CTLA-4 Trafficking and Surface Expression

Overview

Journal Trends Immunol

Specialty Allergy & Immunology

Date 2008 May 13

PMID 18468488

Citations 77

Authors

Elke Valk

Christopher E Rudd

Helga Schneider

Affiliations

Soon will be listed here.

Abstract

The T-cell co-receptor cytotoxic T-cell antigen 4 (CTLA-4) has a strong inhibitory role as shown by the lymphoproliferative phenotype of CTLA-4-deficient mice. Despite its potent effects on T-cell function, CTLA-4 is primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation. Recently, several signalling molecules such as Trim, PLD, ARF-1 and TIRC7 have been described to be involved in the transport of CTLA-4 to the cell surface. Minor changes in surface expression levels have major effects on the outcome of T-cell activation. Optimal regulation of CTLA-4 surface expression is crucial for the balance of stimulatory and inhibitory signals to maximize protective immune responses while maintaining immunological tolerance and preventing autoimmunity.

Citing Articles

Role of lysine-specific demethylase 1 in immunotherapy of gastric cancer: An update.

Ren Y, Gong Y, Zhao H, You D, Li Z, Wang S Chin J Cancer Res. 2025; 36(6):669-682.

PMID: 39802899 PMC: 11724184. DOI: 10.21147/j.issn.1000-9604.2024.06.06.

Identification of a novel molecular classification for hepatocellular carcinoma based on disulfideptosis-related genes and its potential prognostic significance.

Wang T, Liu Y, Kong J, Liu J J Cancer Res Clin Oncol. 2024; 150(12):506.

PMID: 39551857 PMC: 11570565. DOI: 10.1007/s00432-024-06031-7.

Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.

Chand D, Savitsky D, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P Cancer Discov. 2024; 14(12):2407-2429.

PMID: 39083809 PMC: 11609826. DOI: 10.1158/2159-8290.CD-24-0190.

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy.

Nikolouzakis T, Chrysos E, Docea A, Fragkiadaki P, Souglakos J, Tsiaoussis J Cancers (Basel). 2024; 16(11).

PMID: 38893120 PMC: 11171065. DOI: 10.3390/cancers16111995.

CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer.

Oshima K, Shoji H, Boku N, Hirano H, Okita N, Takashima A Am J Cancer Res. 2024; 14(3):1174-1189.

PMID: 38590413 PMC: 10998742. DOI: 10.62347/NQBL9998.

References

Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G . Regulation of CTLA-4 expression during T cell activation. J Immunol. 1996; 156(11):4154-9. View

Utku N, Heinemann T, Tullius S, Bulwin G, Beinke S, Blumberg R . Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity. 1998; 9(4):509-18. DOI: 10.1016/s1074-7613(00)80634-2. View

Gibson H, Hedgcock C, Aufiero B, Wilson A, Hafner M, Tsokos G . Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter. J Immunol. 2007; 179(6):3831-40. PMC: 4290020. DOI: 10.4049/jimmunol.179.6.3831. View

Boasso A, Herbeuval J, Hardy A, Winkler C, Shearer G . Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood. 2004; 105(4):1574-81. DOI: 10.1182/blood-2004-06-2089. View

Barrat F, Le Deist F, Benkerrou M, Bousso P, Feldmann J, Fischer A . Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: a possible mechanism for deregulation of T lymphocyte activation. Proc Natl Acad Sci U S A. 1999; 96(15):8645-50. PMC: 17570. DOI: 10.1073/pnas.96.15.8645. View

Iida T, Ohno H, Nakaseko C, Sakuma M, Arase H, Kominami E . Regulation of cell surface expression of CTLA-4 by secretion of CTLA-4-containing lysosomes upon activation of CD4+ T cells. J Immunol. 2000; 165(9):5062-8. DOI: 10.4049/jimmunol.165.9.5062. View

Vijayakrishnan L, Slavik J, Illes Z, Greenwald R, Rainbow D, Greve B . An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity. 2004; 20(5):563-75. DOI: 10.1016/s1074-7613(04)00110-4. View

Chen W, Jin W, Wahl S . Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med. 1998; 188(10):1849-57. PMC: 2212416. DOI: 10.1084/jem.188.10.1849. View

Cefai D, Schneider H, Matangkasombut O, Kang H, Brody J, Rudd C . CD28 receptor endocytosis is targeted by mutations that disrupt phosphatidylinositol 3-kinase binding and costimulation. J Immunol. 1998; 160(5):2223-30. View

10.

Martin M, Schneider H, Azouz A, Rudd C . Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function. J Exp Med. 2001; 194(11):1675-81. PMC: 2193535. DOI: 10.1084/jem.194.11.1675. View

11.

Egen J, Allison J . Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002; 16(1):23-35. DOI: 10.1016/s1074-7613(01)00259-x. View

12.

Jago C, Yates J, Camara N, Lechler R, Lombardi G . Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol. 2004; 136(3):463-71. PMC: 1809051. DOI: 10.1111/j.1365-2249.2004.02478.x. View

13.

Dillon T, Carey K, Wetzel S, Parker D, Stork P . Regulation of the small GTPase Rap1 and extracellular signal-regulated kinases by the costimulatory molecule CTLA-4. Mol Cell Biol. 2005; 25(10):4117-28. PMC: 1087740. DOI: 10.1128/MCB.25.10.4117-4128.2005. View

14.

Cilio C, Daws M, Malashicheva A, Sentman C, Holmberg D . Cytotoxic T lymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes. J Exp Med. 1998; 188(7):1239-46. PMC: 2212496. DOI: 10.1084/jem.188.7.1239. View

15.

Li R, Perez N, Karumuthil-Melethil S, Prabhakar B, Holterman M, Vasu C . Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells. J Immunol. 2007; 179(8):5191-203. DOI: 10.4049/jimmunol.179.8.5191. View

16.

Kirchgessner H, Dietrich J, Scherer J, Isomaki P, Korinek V, Hilgert I . The transmembrane adaptor protein TRIM regulates T cell receptor (TCR) expression and TCR-mediated signaling via an association with the TCR zeta chain. J Exp Med. 2001; 193(11):1269-84. PMC: 2193385. DOI: 10.1084/jem.193.11.1269. View

17.

Tivol E, Borriello F, Schweitzer A, Lynch W, Bluestone J, Sharpe A . Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5):541-7. DOI: 10.1016/1074-7613(95)90125-6. View

18.

Chuang E, Lee K, Robbins M, Duerr J, Alegre M, Hambor J . Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. J Immunol. 1999; 162(3):1270-7. View

19.

Miller R, Fayen J, Mohammad S, Stein K, Kadereit S, Daum Woods K . Reduced CTLA-4 protein and messenger RNA expression in umbilical cord blood T lymphocytes. Exp Hematol. 2002; 30(7):738-44. DOI: 10.1016/s0301-472x(02)00831-7. View

20.

Kolsch U, Arndt B, Reinhold D, Lindquist J, Juling N, Kliche S . Normal T-cell development and immune functions in TRIM-deficient mice. Mol Cell Biol. 2006; 26(9):3639-48. PMC: 1447406. DOI: 10.1128/MCB.26.9.3639-3648.2006. View